Anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic Human A-1234138 Heavy Chain) Uses, Dosage, Side Effects and more
Anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic Human A-1234138 Heavy Chain) is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
| Trade Name | Anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic Human A-1234138 Heavy Chain) |
| Generic | Lutikizumab |
| Lutikizumab Other Names | Immunoglobulin, anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic human a-1234138 heavy chain), disulfide with synthetic human a-1234138 light chain, dimer, Lutikizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
